A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2023-05-04
Adverse events
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-05 (study day 75); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-20 (study day 90); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-10-05 (study day 136); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-06-29 (study day 404); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-07-01 (study day 406); relationship: not assessed
Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-08-10 (study day 446); relationship: N; serious criteria: hospitalization
Data queries
No data queries.